• Pexmetinib (ARRY-614): Dual Inhibition of p38 MAPK & Tie2 Pa

  2026-05-09

  Pexmetinib (ARRY-614) is a dual inhibitor of p38 MAPK and Tie2 receptor tyrosine kinase, designed to suppress cytokine synthesis and angiogenesis with high specificity and potency. Its molecular activity is validated by both in vitro and in vivo studies, with clear benchmarks for cytokine inhibition and pharmacological impact. This article provides rigorously referenced, structured insights for researchers leveraging Pexmetinib in advanced signaling and inflammation models.

• Optimizing Src Kinase Pathway Research: PP 3 (SKU B7190) in

  2026-05-08

  This article addresses real-world challenges in kinase signaling pathway studies by demonstrating how PP 3 (SKU B7190), a rigorously validated research use only chemical, ensures assay specificity and data reliability. Integrating scenario-based Q&As, we highlight PP 3’s value as a negative control for Src kinase inhibitor PP 2, with practical workflow guidance and literature-backed insights.

• Amikacin (BAY416651) in Antibiotic Resistance Research Workf

  2026-05-08

  Harnessing Amikacin (BAY416651) as a robust bacterial protein synthesis inhibitor enables precise dissection of resistance mechanisms, especially in multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae. This guide details experimental protocols, workflow optimization, and advanced troubleshooting based on the latest epidemiological insights.

• MG-132 (SKU A2585): Reliable Proteasome Inhibition for Cell

  2026-05-07

  This scenario-driven guide demonstrates how MG-132 (SKU A2585) addresses common challenges in apoptosis assays, cell cycle arrest studies, and protein homeostasis workflows. Drawing on recent literature and validated product data, we clarify protocol optimization, data interpretation, and supplier reliability for MG-132 applications—empowering biomedical researchers to generate reproducible, insightful results.

• Assessing pH-Mediated Drug Interactions in Ribociclib Therap

  2026-05-07

  This study applies an Analytical Quality by Design (QbD) framework to rigorously evaluate whether acid-reducing agents, such as proton pump inhibitors, significantly affect the solubility and absorption of ribociclib succinate, a key CDK4/6 inhibitor in breast cancer therapy. The findings demonstrate minimal impact of pH shift on drug bioavailability, providing much-needed clarity for clinicians on co-administration of ribociclib and acid-reducing medications.

• Zosuquidar (LY335979): Redefining MDR Reversal in Oncology

  2026-05-06

  Explore strategic, mechanistic, and translational insights into Zosuquidar (LY335979) 3HCl—a potent P-glycoprotein inhibitor—from APExBIO. This thought-leadership article weaves together cutting-edge evidence, protocol guidance, and competitive context to empower researchers combating multidrug resistance (MDR) in cancer.

• Tenofovir vs Entecavir After HBV-Related HCC Resection: Surv

  2026-05-06

  A large cohort study compared long-term survival outcomes of tenofovir disoproxil and entecavir among patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. The findings indicate that tenofovir disoproxil is associated with improved overall and recurrence-free survival compared to entecavir, informing antiviral strategy selection in this high-risk population.

• Cell Surface Integrity Sets Ploidy Limits in Budding Yeast

  2026-05-05

  Barker et al. (2025) demonstrate that the upper limit of chromosome content in Saccharomyces cerevisiae is governed by cell surface integrity, not solely by genetic or metabolic factors. Their findings reveal that alleviating cell surface stress allows yeast to tolerate higher ploidy, offering new insights into genome duplication, cell size, and adaptation in fungal biology.

• Viral Targeting of RIPK3: Mechanisms Regulating Necroptosis

  2026-05-05

  Liu et al. reveal how orthopoxviruses deploy a viral inducer of RIPK3 degradation (vIRD) to suppress necroptosis and modulate host inflammation. This mechanistic insight elucidates viral immune evasion and suggests new experimental angles for studying ubiquitin-mediated cell death.

• Applied Protocols with Recombinant Human Growth Hormone (GH)

  2026-05-04

  Harness the power of Recombinant Human Growth Hormone (GH) from APExBIO to unravel the IGFBP2-THBS1 axis and optimize cell proliferation assays. This guide delivers actionable workflows, troubleshooting insights, and translational strategies for advanced pituitary and bone growth research.

• ELP-Mediated p21 Delivery Suppresses Glioblastoma Proliferat

  2026-05-04

  This study demonstrates that intracellular delivery of a p21-derived peptide using elastin-like polypeptides (ELPs) effectively suppresses proliferation in multiple glioblastoma cell lines, primarily through cytostatic rather than apoptotic mechanisms. The findings highlight the viability of ELP-based peptide delivery platforms for targeting cell cycle dysregulation in aggressive brain tumors.

• Fangchinoline Restores TFEB-Driven Lysosomal Function in H1N

  2026-05-03

  This study identifies fangchinoline as a potent modulator that restores TFEB-dependent lysosomal biogenesis, counteracting H1N1-induced lysosomal dysfunction and blocking viral entry. The research highlights lysosome-targeted strategies as promising avenues for host-directed antiviral therapy.

• HyperTrap Heparin HP Column: Precision Affinity for Stem Cel

  2026-05-02

  The HyperTrap Heparin HP Column empowers researchers to achieve high-resolution purification of growth factors, nucleic acid enzymes, and coagulation proteins—critical for dissecting cancer stemness. Its robust HyperChrom Heparin HP Agarose medium and exceptional chemical stability streamline experimental workflows for challenging mammary cancer models.

• Bafilomycin C1: Precision Inhibitor for Autophagy Assays

  2026-05-01

  Bafilomycin C1, a potent vacuolar H+-ATPases inhibitor, is pivotal for dissecting lysosomal acidification and autophagy in advanced cell models. This article translates deep-learning-enabled cardiotoxicity screening into actionable workflows, troubleshooting steps, and comparative insights for applied biomedical research.

• Itraconazole: Mechanistic Leverage Against Candida Biofilm R

  2026-05-01

  This thought-leadership article examines how Itraconazole’s unique mechanistic profile—encompassing triazole antifungal action, CYP3A4 inhibition, and signaling pathway modulation—empowers translational researchers to address the persistent challenge of Candida biofilm resistance. Integrating the latest autophagy and biofilm findings, we offer actionable strategies and protocol guidance for maximizing impact in antifungal drug interaction studies and advanced candidiasis models.

16268 records 1/1085 page Next 12345 下5页 Last page